Skip to content

Clinical Effect of Quyou Prescription in the Treatment of Persistent High-risk HPV Infection

Clinical Effect of Quyou Prescription in the Treatment of Persistent High-risk HPV Infection

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006081
Enrollment
Unknown
Registered
2022-06-08
Start date
2022-06-20
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HPV infection

Interventions

Quyou prescription group:Quyou prescription

Sponsors

Fujian Provincial Maternity and Children's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: (1) meet one of the three conditions:?tested positive for HPV16/18 and pathological tissue result of LSIL or below,cervical colposcopy biopsy of LSIL or below,and LSIL lesions less than two years;?tested negative for HPV16 or 18,but positive for other types of high-risk HPV,cytological evidence of ACUS or above,cervical colposcopy biopsy of LSIL or below,and LSIL lesions less than two years;?tested negative for HPV16 or 18,but positive for other types of high-risk HPV,cytological evidence of NILM; (2) homotype HPV infection more than half a year; (3) conforming to the standard of TCM syndrome of dampness and heat; (4) women aged 25-65 with a history of sexual life and regular menstrual cycles; (5) patients with normal liver and kidney function and no history of severe drug allergy; (6) gave informed consent volunteering to participate in the study.

Exclusion criteria

Exclusion criteria: (1) women who were not avoiding pregnancy,were pregnant, or were breastfeeding; (2) those who had used other HPV drugs in the first 3 months of enrollment; (3) patients participating in clinical trials of other drugs.; (4) allergic constitution, such as allergic history of two or more drugs and food,or allergic to the ingredients of a given drug; (5) patients with HSIL or above indicated by cervical biopsy under colposcopy.

Design outcomes

Primary

MeasureTime frame
cervical cytology;clearance rate of Hr-HPV;score of clinical symptom of TCM;

Countries

China

Contacts

Public ContactHuangshan
huangshan0591@126.com13799416433

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026